These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15032625)

  • 1. The utility of proteomic patterns for the diagnosis of cancer.
    Conrads TP; Veenstra TD
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Mar; 4(1):41-50. PubMed ID: 15032625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer diagnosis using proteomic patterns.
    Conrads TP; Zhou M; Petricoin EF; Liotta L; Veenstra TD
    Expert Rev Mol Diagn; 2003 Jul; 3(4):411-20. PubMed ID: 12877381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic patterns for early cancer detection.
    Veenstra TD; Prieto DA; Conrads TP
    Drug Discov Today; 2004 Oct; 9(20):889-97. PubMed ID: 15475322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic proteomics: serum proteomic patterns for the detection of early stage cancers.
    Yu LR; Zhou M; Conrads TP; Veenstra TD
    Dis Markers; 2003-2004; 19(4-5):209-18. PubMed ID: 15258335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein fingerprinting.
    Veenstra TD; Conrads TP
    Curr Opin Mol Ther; 2003 Dec; 5(6):584-93. PubMed ID: 14755884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of advanced proteomics technologies to cancer diagnosis.
    Ciordia S; de Los Ríos V; Albar JP
    Clin Transl Oncol; 2006 Aug; 8(8):566-80. PubMed ID: 16952845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool.
    Conrads TP; Hood BL; Issaq HJ; Veenstra TD
    Mol Diagn; 2004; 8(2):77-85. PubMed ID: 15527321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic patterns: their potential for disease diagnosis.
    Xiao Z; Prieto D; Conrads TP; Veenstra TD; Issaq HJ
    Mol Cell Endocrinol; 2005 Jan; 230(1-2):95-106. PubMed ID: 15664456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
    Seibert V; Ebert MP; Buschmann T
    Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical proteomics: towards early detection of cancers].
    Solassol J; Boulle N; Maudelonde T; Mangé A
    Med Sci (Paris); 2005; 21(8-9):722-9. PubMed ID: 16115457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics to diagnose human tumors and provide prognostic information.
    Ornstein DK; Petricoin EF
    Oncology (Williston Park); 2004 Apr; 18(4):521-9; discussion 529-32. PubMed ID: 15134357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics of cancer of hormone-dependent tissues.
    Tyson DR; Ornstein DK
    Adv Exp Med Biol; 2008; 630():133-47. PubMed ID: 18637489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical proteomics and mass spectrometry profiling for cancer detection.
    Solassol J; Jacot W; Lhermitte L; Boulle N; Maudelonde T; Mangé A
    Expert Rev Proteomics; 2006 Jun; 3(3):311-20. PubMed ID: 16771703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer proteomics.
    Tan HT; Lee YH; Chung MC
    Mass Spectrom Rev; 2012; 31(5):583-605. PubMed ID: 22422534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optomechanical devices for deep plasma cancer proteomics.
    Kosaka PM; Calleja M; Tamayo J
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics.
    Mehan MR; Ostroff R; Wilcox SK; Steele F; Schneider D; Jarvis TC; Baird GS; Gold L; Janjic N
    Adv Exp Med Biol; 2013; 735():283-300. PubMed ID: 23402035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics biomarkers for solid tumors: Current status and future prospects.
    Belczacka I; Latosinska A; Metzger J; Marx D; Vlahou A; Mischak H; Frantzi M
    Mass Spectrom Rev; 2019 Jan; 38(1):49-78. PubMed ID: 29889308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Proteomics and the Elusive Diagnostic Biomarkers.
    Bradshaw RA; Hondermarck H; Rodriguez H
    Proteomics; 2019 Nov; 19(21-22):e1800445. PubMed ID: 31172665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic approaches for serum biomarker discovery in cancer.
    Maurya P; Meleady P; Dowling P; Clynes M
    Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.